The extracellular domain of Her2 in serum as a biomarker of breast cancer
Alexandre Perrier(Assistance Publique – Hôpitaux de Paris), Mathieu Boissan(Inserm), Guillaume Lefèvre(Université de Lille), Joseph Gligorov(Sorbonne Université)
Cited by 88
Related Papers
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
|Annals of Oncology|2020|1.4k
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|724
A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis
|New England Journal of Medicine|2018|605